Tagomics Publishes A New Approach To Genome-wide Epigenomic Profiling

Tagomics Ltd., a pioneering biomarker find and diagnostics company, coming announced nan publication of a peer-reviewed study in Cell Reports Methods, underpinning its epigenomic profiling technology, Active-Seq, nan ground of Tagomics' Activace™  platform. The paper, titled 'Genome-wide profiling of unmodified DNA utilizing methyltransferase-directed tagging and enrichment', built connected investigation from nan University of Birmingham, describes Tagomics' enzymatic attack to epigenomic profiling that targets unmethylated DNA for enrichment, and its exertion to biomarker recognition and illness profiling successful colorectal crab patients.

Current golden modular approaches for assessing genome-wide DNA methylation levels are poorly suited to nan situation of moving successful liquid biopsy (blood) samples, limiting nan capacity of cell-free DNA based diagnostic tests. Addressing these limitations, nan insubstantial describes Active-Seq (Azide Click Tagging for In Vitro Epigenomic sequencing), a guidelines conversion-free methodology that does not change nan underlying DNA series and provides a scalable and broad solution for nan find of caller biomarkers successful liquid biopsy samples. Activace, built connected nan Active-Seq technology, is simply a streamlined workflow that incorporates sequencing room mentation pinch enrichment of unmethylated DNA. The workflow is compatible pinch debased DNA input quantities, down to 1 nanogram, and has been optimized for nan study of DNA methylation successful cfDNA derived from liquid biopsy samples.

The published insubstantial demonstrates exertion of Active-Seq for nan discovery of abnormal DNA methylation signals successful a cohort of colorectal crab patients, identifying thousands of hypomethylated and hypermethylated regions successful tumor-derived tissue, some of which are associated pinch cancer. The study lays nan groundwork for exertion of nan attack to nan deconvolution of nan insubstantial of root of cell-free DNA successful blood, improving discovery and characterization of disease.

This insubstantial is an important milestone for Tagomics, demonstrating nan groundbreaking exertion that underpins our Activace and Interlace platforms. We show that our level enables nan delicate discovery of unmethylated genomic regions, which are cardinal markers for DNA insubstantial of origin. We're excited astir nan penetration this is providing into nan biology of cell-free DNA and are looking guardant to seeing caller applications for nan level successful crab diagnostics and diligent information monitoring for therapeutics."

Dr Robert Neely, CSO and Co-Founder, Tagomics